Moreover, upregulation of SOX4 has been associated with breast cancer and proposed to be the master regulator of epithelial-to-mesenchymal transition34, which again suggests mutants in ZnT2 may impair the secretory phenotype, and may affect risk for breast disease. Here, SLC30A2 is linked to breast cancer.